Oral administration of nanocarrier-packaged CA inhibited CEBPβ transcriptional activity and reduced its interaction with NFkB in an APP/PS1 double transgenic AD mouse model, exhibiting amyloidosis and neuroinflammation. The gene discussed is APP; the disease is Alzheimer disease.